Edition:
United Kingdom

Corcept Therapeutics Inc (CORT.OQ)

CORT.OQ on NASDAQ Stock Exchange Capital Market

11.80USD
15 Feb 2019
Change (% chg)

$0.42 (+3.69%)
Prev Close
$11.38
Open
$11.54
Day's High
$12.14
Day's Low
$11.46
Volume
774,006
Avg. Vol
483,716
52-wk High
$19.97
52-wk Low
$9.14

Latest Key Developments (Source: Significant Developments)

Corcept Therapeutics Reports Q4 Revenue $66.8 Mln
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2018 PRELIMINARY SELECTED FINANCIAL RESULTS; PROVIDES 2019 REVENUE GUIDANCE.Q4 REVENUE $66.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $70.4 MILLION.SEES FY 2019 REVENUE $285 MILLION TO $315 MILLION.2019 REVENUE GUIDANCE OF $285 - $315 MILLION.  Full Article

Judge Denies Teva Pharmaceuticals’ Motion To Dismiss Corcept Therapeutics’ Allegations Of Patent Infringement
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Corcept Therapeutics Inc ::JUDGE DENIES TEVA PHARMACEUTICALS’ MOTION TO DISMISS CORCEPT THERAPEUTICS’ ALLEGATIONS OF PATENT INFRINGEMENT.CORCEPT THERAPEUTICS INC - JUDGE WIGENTON'S DENIAL OF TEVA'S MOTION MEANS THAT CORCEPT'S LAWSUIT WILL PROCEED.  Full Article

Corcept Therapeutics Receives Orphan Designation For Relacorilant As Treatment For Pancreatic Cancer
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Corcept Therapeutics Inc ::CORCEPT THERAPEUTICS RECEIVES ORPHAN DESIGNATION FOR RELACORILANT AS TREATMENT FOR PANCREATIC CANCER.CORCEPT THERAPEUTICS - FDA GRANTED ORPHAN DRUG STATUS TO CORCEPT'S SELECTIVE CORTISOL MODULATOR RELACORILANT TO TREAT PATIENTS WITH PANCREATIC CANCER.  Full Article

Corcept Therapeutics posts Q3 earnings per share $0.11
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Corcept Therapeutics Inc :Corcept Therapeutics announces third quarter 2017 financial results, raises 2017 revenue guidance and provides corporate update.Q3 GAAP earnings per share $0.11.Q3 revenue $42.8 million versus I/B/E/S view $42 million.Q3 earnings per share view $0.14 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $157 million to $162 million.  Full Article